Uncategorized

KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced the appointment of Nicole Sweeny as Chief Commercial Officer.

KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer Read More »

Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet

Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, announced the publication of its Phase 3 CARES 310 study results in The Lancet.

Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet Read More »

Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its Aderamastat Phase 2 Study Results at the European Respiratory Society (ERS) International Congress 2023

Foresee Pharmaceuticals, announced that the company has been selected for a late-breaking oral presentation on the positive primary outcomes of its aderamastat Phase 2 proof-of-concept allergic asthma study at the European Respiratory Society International Congress 2023 taking place in Milan, Italy from September 9-13, 2023.

Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its Aderamastat Phase 2 Study Results at the European Respiratory Society (ERS) International Congress 2023 Read More »

Clinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV Science

Ascletis Pharma Inc. announces that Shanghai Public Health Clinical Center presented clinical results of ASC22 in combination with Chidamide for functional cure of human immunodeficiency virus infection at the 12th International AIDS Society Conference on HIV Science in Brisbane, Australia, and virtually.

Clinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV Science Read More »

CHOP Researchers Validate Pediatric “Allergic March” in Largest National Study of its Kind

Researchers from Children’s Hospital of Philadelphia used electronic health record data from more than 200,000 pediatric patients to describe patterns of pediatric allergies across the United States, validating a population-level pattern of allergy development known as the “allergic march,” in which allergies first present as eczema, followed by food allergies, asthma, and environmental allergies.

CHOP Researchers Validate Pediatric “Allergic March” in Largest National Study of its Kind Read More »

Scroll to Top